Humira® (adalimumab) is a prescription biologic medication developed and sold by AbbVie. It belongs to the class of drugs called tumor necrosis factor‑α (TNF‑α) inhibitors and is used to treat several chronic inflammatory diseases.
| Condition | Typical Humira dosing (adult) |
|-----------|--------------------------------|
| Rheumatoid arthritis (RA) | 40 mg SC every 2 weeks (after a 160 mg loading dose) |
| Crohn’s disease | 160 mg SC at week 0, 80 mg at week 2, then 40 mg SC every 2 weeks |
| Ulcerative colitis | 160 mg SC at week 0, 80 mg at week 2, then 40 mg SC every 2 weeks |
| Plaque psoriasis | 40 mg SC every 2 weeks (after a 160 mg loading dose) |
| Psoriatic arthritis | 40 mg SC every 2 weeks (after a 160 mg loading dose) |
| Ankylosing spondylitis | 40 mg SC every 2 weeks |
| Non‑infectious uveitis | 20–40 mg SC every 4 weeks (or IV for severe cases) |
Note: Doses can be adjusted by a healthcare provider based on disease severity, weight, and response.
---
How It Works
Humira is a fully human IgG1κ monoclonal antibody that binds to soluble and membrane‑bound TNF‑α, neutralizing this key inflammatory cytokine. By blocking TNF‑α, the drug reduces inflammation, pain, and joint damage in the diseases listed above.
Administration
- Route: Subcutaneous injection (under the skin)
- Typical self‑injection sites: Abdomen, upper arm, or thigh
- Preparation: Reconstitute the powder with sterile water or saline, then inject using a pre‑filled syringe or autoinjector.
Common Side Effects
- Injection‑site reactions (pain, redness, swelling)
- Upper respiratory tract infections (cold, flu)
- Headache, fatigue, nausea
- Rarely, reactivation of latent tuberculosis or hepatitis B, demyelinating disease, and serious infections.
Serious Risks
- Infections: TB, hepatitis B, opportunistic infections. Screening before initiation is mandatory.
- Cancer: Slight increased risk of lymphoma and skin cancers has been reported; long‑term data are still being evaluated.
- Autoimmune events: Rare cases of vasculitis, lupus‑like syndrome, or demyelinating disease.
Contraindications
- Active systemic infections
- Uncontrolled TB or hepatitis B/C
- Known hypersensitivity to adalimumab or any component of the formulation
Drug Interactions
- Other immunosuppressants (e.g., methotrexate, cyclosporine) – may increase infection risk.
- Live vaccines – should be avoided; only inactivated vaccines are safe.
- TB skin test and hepatitis B screening are required before starting therapy.
Pregnancy & Lactation
- Pregnancy: Classified as Category C. Limited human data; benefits vs. risks must be weighed.
- Lactation: Adalimumab is excreted in breast milk. Generally, breastfeeding is discouraged during treatment.
Cost & Access
Humira is a high‑cost biologic.
- Average wholesale price: Roughly $2,000–$3,000 per month (varies by region).
- Insurance: Most private plans cover it, often after a prior‑authorization process.
- Patient assistance: AbbVie offers a Humira Patient Assistance Program (PAP) to help eligible patients.
Recent Developments
- Patents: The original Humira patents expired in 2016; AbbVie secured additional patents on drug delivery systems and manufacturing methods, extending market exclusivity.
- Generic competition: Several biosimilar versions (e.g., Amjevita®, Cyltezo®, Amjevita®) entered the U.S. market in 2019, offering lower‑priced alternatives.
- COVID‑19: Early reports suggested that TNF‑α inhibitors might modulate severe inflammatory responses, but their use in acute COVID‑19 is not routine.
How to Talk to Your Doctor
If you’re considering or are already on Humira:
1. Screening: Ask about TB, hepatitis B/C tests.
2. Vaccinations: Get any required inactivated vaccines before starting therapy.
3. Monitoring: Regular follow‑up visits, labs (CBC, LFTs), and watch for infections.
4. Reporting: Contact your healthcare provider promptly if you develop fever, persistent cough, or new skin lesions.
---
Bottom line:
Humira is a well‑established biologic for several autoimmune and inflammatory conditions. It offers significant disease control for many patients but requires careful monitoring for infections and other side effects. Discuss your individual situation—including medical history, insurance coverage, and cost—with your prescribing provider to determine if Humira or a biosimilar is right for you.